Don Hardison Joins the Board of Directors for HTG Molecular Diagnostics
“We are incredibly honored to have Don join our Board,” said TJ Johnson, President and CEO of HTG Molecular Diagnostics. “Don’s career experience, industry knowledge and leadership capabilities will be tremendous assets for our Board and management team.”
Mr. Hardison was most recently the President and CEO, and served on the board of directors, of Good Start Genetics from
“I am very excited to have the opportunity to work with TJ, his team and the Board as they continue their important work in democratizing NGS-based molecular profiling. I believe the company’s technology has the potential to enable more precise diagnosis and delivery of individually tailored treatment at the local level.” stated Mr. Hardison.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the newly formed SAB and its expected benefits to us, the role that immune system biomarkers will have in clinical settings, including patient stratification, and our business and the capabilities of our technology. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management's current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, risks associated with our ability to successfully develop markets for our products, whether by democratization or otherwise, and our ability to successfully develop and commercialize diagnostic products, including more precise or individually tailored clinical solutions. These and other factors are described in greater detail in our filings with the
Westwicke Partners Jamar IsmailPhone: 415-513-1282 Email: email@example.com TJ Johnson President / CEO HTG Molecular DiagnosticsPhone: 520-547-2827 x130 Email: firstname.lastname@example.org